WallStSmart

Alcon AG (ALC)vsFemasys Inc (FEMY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 504436% more annual revenue ($10.40B vs $2.06M). ALC leads profitability with a 9.4% profit margin vs 0.0%. ALC earns a higher WallStSmart Score of 49/100 (D+).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

FEMY

Avoid

23

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued

Intrinsic value data unavailable for FEMY.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

FEMY1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
31.4%10/10

Revenue surging 31.4% year-over-year

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

FEMY4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$33.17M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-3.8%2/10

ROE of -3.8% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : FEMY

The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 31.4% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : FEMY

The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

ALC profiles as a value stock while FEMY is a hypergrowth play — different risk/reward profiles.

ALC carries more volatility with a beta of 0.70 — expect wider price swings.

FEMY is growing revenue faster at 31.4% — sustainability is the question.

ALC generates stronger free cash flow (489M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (49/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Femasys Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Femasys Inc. is an innovative medical technology firm at the forefront of transforming women's healthcare through its proprietary solutions aimed at diagnosing and treating gynecological conditions. The company is particularly recognized for its flagship products that offer non-surgical alternatives for common issues such as uterine fibroids and contraception, positioning it as a leader in the evolving landscape of women's health. As demand for minimally invasive procedures grows, Femasys is strategically positioned to capitalize on this trend, enhancing patient outcomes while optimizing healthcare delivery. With a commitment to addressing significant unmet needs in women's health, Femasys aims to revolutionize the standards of care in this vital sector.

Want to dig deeper into these stocks?